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Abstract
Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase, which
was associated with insulin resistance. Dimethylarginine dimethylaminohydrolase (DDAH) is the major determinant of
plasma ADMA. Examining data from the DIAGRAM+ (Diabetes Genetics Replication And Meta-analysis), we identified a
variant (rs9267551) in the DDAH2 gene nominally associated with type 2 diabetes (P=3 610
25).
Methodology/Principal Findings: initially, we assessed the functional impact of rs9267551 in human endothelial cells
(HUVECs), observing that the G allele had a lower transcriptional activity resulting in reduced expression of DDAH2 and
decreased NO production in primary HUVECs naturally carrying it. We then proceeded to investigate whether this variant is
associated with insulin sensitivity in vivo. To this end, two cohorts of nondiabetic subjects of European ancestry were
studied. In sample 1 (n=958) insulin sensitivity was determined by the insulin sensitivity index (ISI), while in sample 2
(n=527) it was measured with a euglycemic-hyperinsulinemic clamp. In sample 1, carriers of the GG genotype had lower ISI
than carriers of the C allele (67633 vs.79644; P=0.003 after adjusting for age, gender, and BMI). ADMA levels were higher in
subjects carrying the GG genotype than in carriers of the C allele (0.6860.14 vs. 0.5760.14 mmol/l; P=0.04). In sample 2,
glucose disposal was lower in GG carriers as compared with C carriers (9.364.1 vs. 11.064.2 mg6Kg
21 free fat mass6min
21;
P=0.009).
Conclusions/Significance: A functional polymorphism of the DDAH2 gene may confer increased risk for type 2 diabetes by
affecting insulin sensitivity throughout increased ADMA levels.
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Introduction
Endothelial dysfunction is thought to be an early abnormality in
the development and progression of atherosclerosis [1,2]. Several
lines of evidences suggest that endothelial dysfunction is associated
with insulin-resistance states, including obesity, dyslipidemia, and
hypertension [3–6]. Furthermore, it has been reported that
endothelial dysfunction predicts type 2 diabetes mellitus indepen-
dently from other well-known diabetes risk factors [7–9].
Endothelial dysfunction is a broad term that implies reduced
production and/or availability of nitric oxide (NO). Inhibition of
NO synthesis by endogenous inhibitors of the endothelial NO
synthase (eNOS) may play an important role in inducing
endothelial dysfunction [10]. A decreased NO bioavailability
may also have a significant impact on the development of insulin
resistance; NO modulates insulin-mediated glucose disposal as well
as vessels reactivity in insulin-sensitive tissue such as the skeletal
muscle [11]. It has been shown that changes in insulin-mediated
capillary recruitment are positively correlated with changes in
insulin-stimulated glucose disposal [12]. Moreover, mice with a
genetic disruption of endothelial NOS exhibit insulin resistance
caused by reduction in both microvascular recruitment and muscle
glucose uptake in response to insulin [13]. Asymmetric dimethy-
larginine (ADMA) is a naturally occurring methylated arginine
that inhibits the synthesis of NO from L-arginine thus impairing
endothelium-dependent vasodilation [14,15]. Elevated plasma
levels of ADMA have been reported in several clinical syndromes
associated with increased cardiovascular disease risk, including
type 2 diabetes [16–21], and have been associated with insulin
resistance [22–24]. There is evidence that treatment with
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reduces plasma ADMA concentration in insulin-resistant subjects
with hypertension [22]. ADMA is generated by methylation of
proteins by the protein arginine N-methyltransferases (PRMTs),
and is metabolised by the dimethylarginine dimethylaminohydro-
lase (DDAH) [25,26]. Two isoforms of DDAH have been
identified, with DDAH1 found in tissues expressing neuronal
NOS, and DDAH2 highly expressed in the endothelium [27].
Transgenic mice over-expressing DDAH1 exhibit reduced ADMA
levels, which are associated with an increased production of NO,
and enhanced insulin sensitivity [28,29]. At the molecular level,
transgenic mice over-expressing DDAH1 show an enhanced
hepatic Akt phosphorylation. Exogenous administration of ADMA
to normal mice results in an impaired insulin-stimulated glucose
incorporation into glycogen in skeletal muscle; these data support
the hypothesis that ADMA may modulate insulin sensitivity, by
decreasing NO synthesis [29].
In view of the important role of ADMA in regulating
endothelium-dependent vasodilation and, thereby, insulin sensi-
tivity, we hypothesized that polymorphisms in the DDAH2 gene,
potentially altering its expression or activity, may be associated
with type 2 diabetes. Therefore, we interrogated the Diabetes
Genetics Replication And Meta-analysis (DIAGRAM+) Consor-
tium database [30] to investigate if the three polymorphisms
potentially affecting DDAH2 gene expression were associated with
type 2 diabetes. One variant (rs9267551) in the DDAH2 gene was
nominally associated with type 2 diabetes (P=3 610
25), although
this association did not reach genome-wide significance
(P,5610
28), with the G diabetogenic risk allele conferring an
odds ratio (OR) of 1.12 (95% CI 1.06–1.19) (Andrew Morris and
Mark McCarthy personal communication for the DIAGRAM+).
The two other variants (rs805305 and rs707916) in perfect linkage
disequilibrium (r
2=1.0), supposed to have functional effects
[31,32] on ADMA levels, were not associated with type 2 diabetes
(OR=1.02, 95% CI 0.98–1.07) (Andrew Morris and Mark
McCarthy personal communication for the DIAGRAM+). Since
rs9267551 variant is located in a regulatory region of DDAH2
comprising consensus binding motifs sequences recognized by Egr
and EF2 trancription factors families [33], we performed a
functional analysis in endothelial cells and found that the
rs9267551 polymorphism can act as a modulator of mRNA
expression of DDAH2, and, then, investigated whether rs9267551
genotypes were associated with insulin sensitivity in two indepen-
dent samples of nondiabetic subjects of European ancestry.
Materials and Methods
Cell cultures
Umbilical cords were obtained from randomly selected healthy
mothers delivering at the Pescara Town Hospital who had signed
a written consent form. Umbilical cord arteries were screened for
the polymorphism of interest as described below. Primary
HUVECs were obtained as previously described [34,35] and
cultured in EGM-2 medium (Cambrex Bioscience, East Ruther-
ford, NJ) supplemented with 2% Fetal Bovine Serum, ascorbic
acid, VEGF, rhIGF-1, hydrocortisone, rhFGF, rhEGF, heparin,
amphotericin B and penicillin/streptomycin. We did not find
HUVECs carrying the C/C genotype since the proportion of
individuals carrying this genotype is very low (,1% in the two
study samples). The immortalized HUVECs cell line was obtained
from Cambrex Bioscience (East Rutherford, NJ) and maintained
in EGM-2 medium.
Constructs preparation and luciferase assay
A 1755 bp fragment of the human DDAH2 gene spanning the
promoter region and the first exon, was obtained by polymerase
chain reaction (PCR) from a human genomic DNA sample and
the variant carrying the rs9267551 C minor allele was generated
using the QuickChange Site-Directed Mutagenesis kit (Stratagene,
Las Vegas, NV). Both fragments were inserted in the pGL3 basic
luciferase expression vector (Promega, Madison, WI) and
constructs sequence was confirmed by direct sequencing. HU-
VECs were seeded on 12-wells plates cotransfected with 0.8 mgo f
either pGL3 rs9267551G, pGL3 rs9267551C or an empty pGL3
vector, and 70 ng phRL-Renilla vector, as an internal control of
transfection efficiency, per well, using lipofectamine transfection
reagents (Invitrogen Co., Carlsbad, CA), according to the
manufacturer protocol. Luciferase activities were determined
24 h after transfection, using the dual luciferase reporter assay
system with a 20/20 luminometer (Promega, Madison, WI).
RNA extraction and Real Time PCR
Total RNA was obtained from primary HUVECs carrying the
different genotypes (G/G and C/G), reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA) and analyzed by Real-Time
quantitative PCR using a Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA) with 10 ng of cDNA and
0.2 mM of the following oligonucleotide primers: FW: 59-
GGTGGTGGGAGGTAAACTGA-39; RV: 59-TCGCGTT-
CTCGTCTCCTATT-39. The human ribosomal protein S9
(RPS9) was amplified using the following oligonucleotide primers:
FW: 59-CTGGGTTTGTCGCAAAACTT-39; RV: 59-GTGG-
GTCCTTCTCATCAAGC-39, and used to normalize the results
according to the Livak method.
Nitric oxide synthase (NOS) activity in HUVECs
HUVECs were starved for 12 h in serum-deprived medium and
NOS activity was determined in duplicate for each cell strain by
measuring the conversion of L-(3H)-arginine into L-(3H)-citrulline
as previously described [34,35]. Data of NOS activity were
normalized to cell protein content.
DNA analysis
DNA was isolated from whole blood using commercial DNA
isolation kit (Promega, Madison, WI). Screening of the rs9267551
polymorphism was performed using a TaqMan allelic discrimina-
tion assay (Applied Biosystems, Foster City, CA). TaqMan
genotyping reaction was amplified on a GeneAmp PCR system
2700 and fluorescence was detected using an ABI Prism 7000
sequence detector (Applied Biosystems, Foster City, CA). Geno-
typing quality was tested by including 12 HapMap samples in each
384-well assay. The agreement rate with the HapMap database
genotypes was .99%.
Study subjects
Two different samples of adult ($18 years of age) nondiabetic
Italians of European ancestry were studied. Diabetes mellitus was
defined as fasting plasma glucose .126 mg/dl, current treatment
with anti-diabetic drugs or self-reported history of a previous
diagnosis.
Sample 1 comprised 958 nondiabetic individuals (438 men and
520 women, age 51.0612.9 years, BMI 30.666.4 kg/m2),
consecutively recruited at the Department of Experimental and
Clinical Medicine of the University ‘Magna Graecia’ of Catanzaro
[36]. All individuals underwent an oral glucose tolerance test
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after glucose load. The Matsuda index [insulin sensitivity index
(ISI)] was calculated as follows: 10,000/square root of [fasting
glucose (millimoles per liter)6fasting insulin (milliunits per
liter)]6[mean glucose6mean insulin during OGTT]. ADMA
concentrations in plasma were measured in 68 subjects by high-
performance liquid chromatography, as previously described [15].
Sample 2 comprised 527 non-diabetic offspring of patients with
type 2 diabetes (228 men and 299 women, age 39.1610.5 years,
BMI 29.266.3 kg/m2) from the EUGENE2 project (http://www.
eugene2.com), consecutively recruited at the Department of
Experimental and Clinical Medicine of the University ‘Magna
Graecia’ of Catanzaro according to previously reported inclusion
criteria [37]. After 12-h overnight fast, subjects underwent a
euglycemic hyperinsulinemic clamp study as previously described
[38,39]. The rate of total insulin-stimulated glucose disposal (M)
was calculated for the last 60 minutes of the insulin infusion, and
normalized per kg of fat-free mass.
All the investigations were performed in accordance with the
principles of the Declaration of Helsinki, and the protocol was
approved by the local ethical committee. All subjects recruited
provided written informed consent.
Statistical analysis
The results for continuous variables are given as means 6 SD.
Unpaired Student’s t test or ANOVA were used to compare
differences of continuous variables between groups, as appropriate
and the x2-test for non-continuous variables. A general linear
model was used to compare phenotypic differences in the two
samples. Power calculations were performed with Quanto version
1.2.4 (http://hydra.usc.edu/gxe; accessed 25 July 2011). The
study had 80% power (for a=0.05) to detect a 15% increase in
insulin sensitivity per copy of allele C in sample 1 and a 17%
increase in insulin sensitivity per copy of allele C in sample 2.
Associations between polymorphism and continuous traits are
presented as effect sizes (b and SE) per copy of the type 2 diabetes
risk allele, estimated by linear regression adjusted for gender, age,
and BMI. We report nominal P value,0.05 without adjustment
for multiple testing given the high prior probabilities for
association of the rs9267551 polymorphism with the examined
phenotype. All analyses were performed using the SPSS software
program Version 16.0 for Windows.
Results
Initially, to evaluate the hypothesis that rs9267551 polymor-
phism may affect DDAH2 transcription, we assessed DDAH2
mRNA levels in primary HUVECs naturally carrying the
rs9267551 GG and CG genotype by Real-Time RT-PCR. We
observed that DDAH2 expression was significantly lower in GG
HUVECs as compared to CG cells (P=0.008; Fig. 1A).
Subsequently, to confirm a direct effect of rs9267551 on DDAH2
transcription levels, we transfected immortalized HUVEC cells
with a luciferase expression vector carrying either the rs9267551 C
or the rs9267551 G allele and evaluated the transcription
efficiency of the luciferase gene 24 hrs after transfection. We
observed that the G allele was associated with a significant
decrease in luciferase activity as compared to the C allele
(P=0.00076; Fig. 1B). Finally, we tested whether rs9267551
polymorphism affects NOS activity, as evaluated by assessing the
conversion of L-[3H]arginine into L-[3H] citrulline in HUVECs
carrying either the GG (n=34) or the CG (n=5) genotype. In the
presence of 1 mM arginine, basal nitric oxide release was lower in
GG HUVECs as compared to CG cells (0.14560.08 and
0.19860.19 pmoles/NO/min/mg protein, respectively) although
these differences did not reach the significance threshold
(P=0.08). By stratifying cell strains according to tertiles of NOS
activity, the proportion of HUVECs displaying a lower NO release
was significantly higher among cells carrying the GG genotype (P
for trend=0.04) (Fig. 2).
Next, we tested the hypothesis that the rs9267551 polymor-
phism was associated with insulin sensitivity in two samples of
nondiabetic individuals. In sample 1 insulin sensitivity was assessed
by the ISI index (calculated from glucose and insulin levels at 0,
30, and 120 min of the OGTT) whereas in sample 2 insulin
sensitivity was directly measured by the euglycaemic-hyperinsu-
linemic clamp, considered as a reference assay for insulin
sensitivity. It is noteworthy that among surrogate indexes of
insulin sensitivity, the ISI index has been showed to have the
highest correlation with insulin-stimulated glucose disposal
measured by the clamp-derived index [40,41].
Clinical characteristics of sample 1 and sample 2 according to
the rs9267551 polymorphism are shown in Table 1. Genotype
distributions were in Hardy-Weinberg equilibrium (P.0.05) in
each study sample. Because of the small number of CC individuals
(n=5) and the a priori hypothesis based on the dominant effect
observed in functional studies in endothelial cells, GC and CC
individuals were pooled and analyzed together as C carriers,
according to a dominant genetic model. The rs9267551
polymorphism did not show any significant association with age,
gender, and body mass index (BMI) (Table 1), whereas it was
significantly associated with insulin sensitivity, as estimated by the
ISI index, with subjects carrying the GG genotype having
significantly lower insulin sensitivity as compared with carriers of
the C allele (67633 vs. 79644, respectively; P=0.003 after
adjusting for age, gender, and BMI) (Table 1). ADMA
concentrations in plasma were available for 60 subjects carrying
the GG genotype, and 8 carriers of the C allele (7 subjects carrying
the GC genotype and 1 subject carrying the CC genotype).
ADMA levels were significantly higher in subjects carrying the GG
genotype as compared with carriers of the C allele (0.6860.14 vs.
0.5760.14 mmol/l, respectively; P=0.04 after adjusting for age,
gender, and BMI).
In order to get further insights on the role of the rs9267551
polymorphism on insulin sensitivity, an additional sample of
individuals who underwent a euglycaemic-hyperinsulinemic clamp
assay was analysed. Insulin sensitivity assessed as insulin-stimulated
glucose disposal was significantly lower in subjects carrying the
GG genotype as compared with carriers of the C allele (9.364.1
vs. 11.064.2 mg6Kg
21 free fat mass6min
21, respectively;
P=0.03 after adjusting for age, gender, and BMI) (Table 1).
Discussion
Endothelial dysfunction has been associated with insulin
resistance and incident type 2 diabetes [3–9]. ADMA is an
endogenous competitive inhibitor of eNOS and its elevation may
account for reduced NO generation observed in states of insulin
resistance [22–24]. Plasma ADMA levels have been shown to be
elevated in patients with type 2 diabetes [21], and have been
associated with insulin resistance [22–24]. Metabolism of ADMA
by DDAH is most likely the major determinant of plasma ADMA
concentration [25,26]. Examining data from the DIAGRAM+
meta-analysis for genes involved in endothelial function led us to
the identification of a variant (rs9267551) in the DDAH2 gene
nominally associated with type 2 diabetes (P=3 610
25). To find
further support for the role of DDAH2 in the pathogenesis of type 2
diabetes, we examined the functional impact of this polymorphism
DDAH2 Polymorphism and Insulin Sensitivity
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lower transcriptional activity resulting in reduced expression of
DDAH2 in primary HUVECs naturally carrying the GG genotype.
Therefore, considering the down-regulation of DDAH2,a
prediction of our in vitro study was that plasma ADMA levels
would be higher in carriers of the GG genotype. To verify this
conjecture, we measured circulating ADMA concentrations in 68
subjects for whom plasma samples were available. According to
our hypothesis, individuals carrying the GG genotype exhibited
ADMA levels significantly higher than carriers of the C allele.
Importantly, these data are consistent with those recently reported
showing that the TGCCCAGGAG haplotype of DDAH2,
including the G variant of rs9267551, is associated with increased
ADMA levels (P=0.0012) [42].
Glucose uptake and metabolism in the skeletal muscle accounts
for almost 90% of whole-body glucose disposal in humans [43];
endothelium-derived NO mediates insulin-induced stimulation of
skeletal muscle perfusion, and there is evidence that the
stimulation of muscle blood flow by insulin promotes substrate
delivery and thereby may regulate insulin sensitivity in the skeletal
muscle [44]. Accordingly, it has been shown that eNOS knockout
mice exhibit a 40% lower insulin-stimulated glucose uptake than
control mice as assessed by hyperinsulinemic euglycemic clamp
assay [13]. Given the strong association between insulin sensitivity
and endothelial function, we next examined the impact of the
rs9267551 polymorphism on in vivo insulin sensitivity in two
samples of nondiabetic individuals. We found that, as compared
with carriers of the C allele, individuals carrying the GG genotype
Figure 1. Functional effects of the rs9267551 polymorphism. A. Quantification of DDAH2 mRNA levels in primary HUVECs naturally carrying
the G/G (n=10) or C/G genotype (n=5). Total RNA was extracted from confluent cells. cDNA was reverse transcripted and analyzed by quantitative
Real-Time PCR technique. Bars represent the means 6 SD of two independent experiments carried out in triplicate (*P=0.008 for G/G HUVECs vs C/G
HUVECs); B. Luciferase activity was evaluated in immortalized HUVEC transfected with an empty PGL3 luciferase vector (PGL3, light gray bar, n=21);
or a PGL3 vector carrying the rs9267551 G (PGL3G, white bar, n=21); or a PGL3 vector carrying the rs9267551 C form (PGL3C, black bar, n=21).
Luciferase activity in mock transfected cells (mock, dark gray bar, n=21) was assessed as a control. (**P=0.00076 for PGL3G vs. PGL3C).
doi:10.1371/journal.pone.0036224.g001
Figure 2. Stratification of HUVEC strains according to tertiles of NOS activity (%). The proportion of HUVECs displaying a lower NO release
was significantly higher among cells carrying the GG genotype (P for trend=0.04).
doi:10.1371/journal.pone.0036224.g002
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OGTT-derived ISI, an index of muscle insulin sensitivity strongly
correlated with insulin-stimulated total glucose disposal during the
euglycemic clamp [45]. These results were confirmed in a second
independent sample in which insulin sensitivity was measured by the
gold-standard technique, the euglycaemic–hyperinsulinaemic clamp.
Interestingly, we did not observe any association between the
rs9267551 polymorphism in the DDAH2 gene and the HOMA index
of hepatic insulin resistance (data not shown). These results are
consistent with those reported by Stuhlinger et al. [22] showing a
significant correlation of plasma ADMA levels with direct measures of
insulin-mediated glucose disposal, but not with fasting plasma glucose
and insulin levels (the two variables that are used to calculate the
HOMA index) in a cohort of nondiabetic individuals. Taken together,
these findings suggest that the rs9267551 polymorphism in the
DDAH2 gene through its effects on ADMA levels may impair eNOS
activity and NO production resulting in an impaired insulin-
stimulated glucose disposal predominantly in skeletal muscle. Our
observation that GG HUVECs show a decreased basal NO
production offers experimental support to this hypothesis.
The relative homogeneity of study samples with all individuals
being Whites of European ancestry represents a strength of this
study. An additional strength is constituted by the functional ‘‘in
vitro’’ data obtained in human endothelial cells. As a matter of
fact, HUVECs are a uniquely suited model to demonstrate a direct
effect of a DDAH2 genetic variant in human endothelium; in fact
the in vitro data reported in the study shed light on the molecular
mechanism of the association between DDAH2 and type 2 diabetes
observed in the DIAGRAM+ meta-analysis. Indeed, once a
putative causal variant has been identified by GWA studies, there
is the need to obtain functional confirmation that it is truly causal,
and to reconstruct the molecular and physiological mechanisms
underlying its impact on the phenotype of interest. Our study,
showing the direct influence of the rs9267551 variant on ADMA
levels and endothelial function, provides one of the first examples
of a SNP identified in GWAs that has a clear functional impact
relevant to mechanisms of the disease.
Nonetheless, this study has some limitations. The present
findings obtained in a cross-sectional study of cohorts of European
ancestry are explorative in nature and replication in independent
prospective population-based studies is needed to firmly determine
whether the rs9267551 polymorphism affects ADMA levels and
insulin sensitivity. A second limitation is that although the results
were replicated in two independent samples of Whites of
European ancestry, they may not apply to populations of different
ethnicity. Another limitation is represented by the very small
number of carriers of the C allele of the rs9267551 variant; our
finding implies that since the at-risk GG genotype is found in the
majority of the general population, DDAH2 gene variant(s) have a
minor role in the genetic susceptibility to insulin-resistance. This
minor role is indeed compatible with the fact that the association
of DDAH2 gene variants with type 2 diabetes did not reach
genome-wide significance in previous studies. Finally, a major
problem in genetic association studies of complex disease is the
inconsistency of replication due to small sample size. However, it is
worthy to note that: 1) the consistency of the results observed both
as risk of type 2 diabetes in the DIAGRAM+ meta-analysis and as
intermediate phenotype such as insulin resistance argues against a
chance finding; 2) the hypotheses in this study were defined a
priori, are biologically plausible and the ‘‘in vitro’’ results are
consistent with the ‘‘in vivo’’ data. We therefore believe that our
findings are likely to be true.
In conclusion, our data indicate that a functional polymorphism
in the DDAH2 gene may confer increased risk of type 2 diabetes by
affecting insulin sensitivity due to an increase in circulating ADMA
levels. Although the present findings cannot be presently claimed
as definitive, they have to be considered as hypotheses generating
and should be replicated in further investigations.
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